Coronary Artery Disease clinical trials
131 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- Virtue® SAB in the Treatment of Coronary ISR Trial
- A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
- The Bridging Antiplatelet Therapy With Cangrelor 2 Study
- AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
- The Switching Antiplatelet-9 (SWAP-9) Study
- MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
- MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels
- Prevent Cardiac Surgery Associated AKI Trial
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI
- Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study
- Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
- Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)
- Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention
- Colchicine's Effect on Inflammatory Markers
- Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
- Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.
- Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors
- Clinical and Biochemical Effects of a Defined Plant-Based Diet on Heart Disease
- Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement
- Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
- Randomization of Single vs Multiple Arterial Grafts
- Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease
- Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease
- A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)
- Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)
- The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial
- FORWARD CAD IDE Study
- PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm
- A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
- The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
- Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
- SELUTION 4 De Novo Small Vessel IDE Trial
- Intravascular Lithotripsy With or Without Rotational Atherectomy for Coronary Calcified Nodule Treatment
- Implementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease
- Prevail Global Study
- Focused Orticumab Research for Treating Inflammation in Coronary Arteries
- Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment
- MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
- REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women
- REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Minorities
- Effectiveness of Remote Ischemic Preconditioning for Prevention of Contrast Induced Acute Kidney Injury in Patients Undergoing Coronary Angiograms.
- Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
- The Relationship Between Blood Flow Readings During Surgery and How Well the Graft Stays Open and How Patients Recover Afterward in Coronary Artery Bypass Graft Surgery
- Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
- AI Detection of Incidental Coronary Artery Calcium to Enhance Cardiovascular Disease Prevention
- One-Month DAPT in CABG Patients
- CTSN Embolic Protection Trial
- Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial
- Evaluating New Radiation Techniques for Cardiovascular Imaging
- PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Coronary Artery Disease” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.